Instil Bio, Inc. (TIL)
| Market Cap | 2.34B |
| Revenue (ttm) | 51,000 |
| Net Income (ttm) | n/a |
| Shares Out | 128.74M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,609 |
| Open | 18.06 |
| Previous Close | 18.13 |
| Day's Range | 17.61 - 18.45 |
| 52-Week Range | 14.42 - 29.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorpo...
Financial Performance
Financial StatementsNews
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
IPO in March 2021 raising $368M in gross proceeds
At a Recent Cancer Research Conference, Instil Bio Stole the Show
The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association...
67% overall response rate and 19% complete response rate in 21 patients
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additio...
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
The IPO Market Had A Busy Week
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
Instil Bio Announces Pricing of Upsized Initial Public Offering
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Cancer biotech Instil Bio files for a $100 million IPO
Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Instil Bio IPO Registration Document (S-1)
Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.